Back to Search
Start Over
Second-line paclitaxel in non-small cell lung cancer initially treated with cisplatin: a study by the European Lung Cancer Working Party.
- Source :
-
British journal of cancer [Br J Cancer] 2007 Jun 04; Vol. 96 (11), pp. 1644-9. Date of Electronic Publication: 2007 May 01. - Publication Year :
- 2007
-
Abstract
- In the context of a phase III trial comparing in advanced non-small cell lung cancer (NSCLC) sequential to conventional administration of cisplatin-based chemotherapy and paclitaxel, we evaluated the activity of paclitaxel as second-line chemotherapy and investigated any relation of its efficacy with the type of failure after cisplatin. Patients received three courses of induction GIP (gemcitabine, ifosfamide, cisplatin). Non-progressing patients were randomised between three further courses of GIP or three courses of paclitaxel. Second-line paclitaxel was given to patients with primary failure (PF) to GIP and to those progressing after randomisation to further GIP (secondary failure or SF). One hundred sixty patients received second-line paclitaxel. Response rates were 7.7% for PF and 11.6% for SF (P=0.42). Median survival times (calculated from paclitaxel start) were 4.1 and 7.1 months for PF and SF (P=0.002). In multivariate analysis, three variables were independently associated with better survival: SF (hazard ratio (HR)=1.55, 95% confidence interval (CI) 1.08-2.22; P=0.02), normal haemoglobin level (HR=1.56, 95% CI 1.08-2.26; P=0.02) and minimal weight loss (HR=1.79, 95% CI 1.26-2.55; P=0.001). Paclitaxel in NSCLC patients, whether given for primary or for SF after cisplatin-based chemotherapy, demonstrates activity similar to other drugs considered active as second-line therapy.
- Subjects :
- Adult
Aged
Aged, 80 and over
Antineoplastic Agents therapeutic use
Antineoplastic Combined Chemotherapy Protocols therapeutic use
Carcinoma, Non-Small-Cell Lung mortality
Chemotherapy, Adjuvant
Deoxycytidine administration & dosage
Deoxycytidine analogs & derivatives
Europe
Female
Humans
Ifosfamide administration & dosage
Lung Neoplasms mortality
Male
Middle Aged
Survival Analysis
Treatment Failure
Gemcitabine
Carcinoma, Non-Small-Cell Lung drug therapy
Cisplatin administration & dosage
Lung Neoplasms drug therapy
Paclitaxel therapeutic use
Subjects
Details
- Language :
- English
- ISSN :
- 0007-0920
- Volume :
- 96
- Issue :
- 11
- Database :
- MEDLINE
- Journal :
- British journal of cancer
- Publication Type :
- Academic Journal
- Accession number :
- 17473825
- Full Text :
- https://doi.org/10.1038/sj.bjc.6603772